API- Carfilzomib

Packaging- Single Vial

Strength- 60 mg

Get an Enquiry


Carfilzomib is an anti-cancer drug indicated for use as a selective proteasome inhibitor for the treatment of:

Multiple Myeloma: Patients who have taken at least two prior therapies including treatment with Lenalidomide and Bortezomib.

Dosage and Side Effects

Carfilzomib should be given by the health care providers. It comes as a powder to be mixed with the liquid in order to inject it into veins.

Some most common adverse reactions include fever, chills, weakness, diarrhea, joint/bone pain, shortness of breath, vomiting, nausea, and dizziness.

Also, serious side effects include vision changes, chest pain, extreme tiredness, blood in the urine and confusion.

Warning and Precautions

  • Females of childbearing potential must be advised to quit the intention of conceiving a baby while on Carfilnat. It may cause fetal harm.
  • If you`re allergic to Carfilnat Injection, talk to your health care provider. They can interrupt the dose according to the circumstances.
  • In the condition of medical history includes chronic diseases, carefully take Carfilnat after the consent of your doctor.


Is carfilzomib injection FDA-approved?

Yes. The FDA must first approve generic drugs before they are marketed. The FDA requires that generic drugs must be as high in quality, and as strong, pure and stable as brand name drugs.
What is the use of Carfilzomib?

Carfilzomib is an anti-cancer medication used for the treatment of patients suffering from multiple myeloma.

In what form carfilzomib generally comes?

Carfilzomib generally comes in the form of powder, to be mixed with liquid to be injected intravenously.
What type of drug is Carfilzomib?
Carfilzomib comes in the class of proteasome inhibitors recommended for the treatment of multiple myeloma.